RPG Life Sciences credit ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendLast 12Mto Sep 2026FY26Mar 2026FY22 and earlierAlpha Plus
20.020.0
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
−255−255
0.03×0.03×
−0.42×−0.42×
0.14×0.14×
−1.63×−1.74×
141.13×141.13×
2.3%3.2%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

RPGLIFE₹2,844.00

RPG Life Sciences Limited

· Pharma & Health
₹ CrorePeersGUFICBIOGUJTHEMUNICHEMLABORCHPHARMASMSPHARMAFDCIOLCPINDSWFTLABMcap ₹4,703 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/09/2026
Total Debt———20.020.0
Net Debt———-255.5-255.5
Total Debt/Equity———0.030.03
Net Debt/Equity———-0.42-0.42
Total Debt/EBITDA———0.140.14
Net Debt/EBITDA———-1.74-1.63
Interest Coverage (EBIT/Interest)———141.13141.13
Total Debt/Total Capital %———3.202.26
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.